Table 3.
Cox regression hazard model to predict the effect on OS
| Category | HR | 95% CI | P-value |
|---|---|---|---|
| Patient age (years) | 0.026 | ||
| ≤35 | 0.961 | 0.285–3.238 | 0.949 |
| 36–50 | 0.136 | 0.032–0.583 | 0.007 |
| >50 | |||
| Tumor size (mm) | 0.016 | ||
| ≤20 | 0.123 | 0.029–0.516 | 0.004 |
| 21–50 | 0.478 | 0.176–1.296 | 0.147 |
| >50 | |||
| Cancer stage | 0.002 | ||
| DCIS | 0.000 | 0.000–6.264E+296 | 0.971 |
| I | 0.050 | 0.006–0.387 | 0.004 |
| II | 0.277 | 0.124–0.619 | 0.002 |
| III | |||
| LN status | 0.003 | ||
| 0 | 0.188 | 0.070–0.507 | 0.001 |
| 1–3 | 0.727 | 0.271–1.955 | 0.528 |
| ≥4 | |||
| Histologic grade | 0.296 | ||
| I–II | 0.000 | 0.000–6.264E+296 | 0.981 |
| II–III | 0.439 | 0.512–1.631 | 0.124 |
| III | 1.212 | 0.480–2.296 | 0.744 |
| Unknown and DCIS | |||
| Embolus | 1.238 | 0.445–3.443 | 0.682 |
| Chemotherapy | 0.851 | ||
| No | 2001.174 | 0.075–2.718E+87 | 0.936 |
| Anthracycline-based | 2727.280 | 0.131–3.9E+87 | 0.933 |
| Taxane | 3573.678 | 0.190–5.056E+87 | 0.931 |
| Others | |||
| History of mother suffered BC | 1.943 | 0.263–14.378 | 0.515 |
| Menopause | 0.431 | 0.180–1.033 | 0.059 |
| Sex hormone receptor | 1.050 | 0.476–2.316 | 0.905 |
| Endocrine therapy | 0.677 | 0.280–1.636 | 0.386 |
| Radiotherapy | 0.720 | 0.323–1.604 | 0.422 |
| Ki-67 (%) | |||
| ≤14 | 0.581 | 0.162–2.082 | 0.404 |
| >14 | |||
| BMI (kg/m2) | 0.417 | ||
| <18.5 | 0.851 | 0.112–6.473 | 0.876 |
| 18.5–23.9 | 0.578 | 0.256–1.304 | 0.187 |
| ≥24 |
Abbreviations: BC, breast cancer; BMI, body mass index; DCIS, ductal carcinoma in situ; HR, hazard ratio; LN, lymph node; OS, overall survival.